Cargando…

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials

BACKGROUND: Two novel type 2 oral poliovirus vaccine (OPV2) candidates, novel OPV2-c1 and novel OPV2-c2, designed to be more genetically stable than the licensed Sabin monovalent OPV2, have been developed to respond to ongoing polio outbreaks due to circulating vaccine-derived type 2 polioviruses. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Coster, Ilse, Leroux-Roels, Isabel, Bandyopadhyay, Ananda S, Gast, Christopher, Withanage, Kanchanamala, Steenackers, Katie, De Smedt, Philippe, Aerssens, Annelies, Leroux-Roels, Geert, Oberste, M Steven, Konopka-Anstadt, Jennifer L, Weldon, William C, Fix, Alan, Konz, John, Wahid, Rahnuma, Modlin, John, Clemens, Ralf, Costa Clemens, Sue Ann, Bachtiar, Novilia S, Van Damme, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811203/ https://www.ncbi.nlm.nih.gov/pubmed/33308429 http://dx.doi.org/10.1016/S0140-6736(20)32541-1

Ejemplares similares

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials
por: Sáez-Llorens, Xavier, et al.
Publicado: (2021)

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials( )
por: Gast, Christopher, et al.
Publicado: (2021)

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study
por: Van Damme, Pierre, et al.
Publicado: (2019)

Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children
por: Wahid, Rahnuma, et al.
Publicado: (2022)

A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2020)

Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique
por: de Deus, Nilsa, et al.
Publicado: (2020)

Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3
por: Yeh, Ming Te, et al.
Publicado: (2023)

Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response, Philippines
por: Alipon, SweetC B, et al.
Publicado: (2022)

Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials
por: Wahid, Rahnuma, et al.
Publicado: (2022)

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization
por: Sarnquist, Clea, et al.
Publicado: (2018)

Quantitative RT-PCR Assays for Quantification of Undesirable Mutants in the Novel Type 2 Oral Poliovirus Vaccine
por: Manukyan, Hasmik, et al.
Publicado: (2022)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults
por: Leroux-Roels, Isabel, et al.
Publicado: (2020)

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States
por: Marin, Mona, et al.
Publicado: (2017)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Development of a Quantitative One-Step RT-PCR Method for the Detection of Sabin 2 Virus Contamination in a Novel Oral Poliovirus Vaccine Type 2
por: Manukyan, Hasmik, et al.
Publicado: (2021)

Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal()
por: Harutyunyan, Vachagan, et al.
Publicado: (2023)

Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB)
por: Cowley, Daniel, et al.
Publicado: (2019)

Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine — Worldwide, 2013–2016
Publicado: (2015)

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

The role of a genetically stable, novel oral type 2 poliovirus vaccine in the poliomyelitis endgame
por: Costa Clemens, Sue Ann, et al.
Publicado: (2023)

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
por: Resik, Sonia, et al.
Publicado: (2018)

Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar
por: Razafindratsimandresy, Richter, et al.
Publicado: (2018)

III. Factors Influencing the Acceptance of Oral Poliovirus Vaccine
por: Cohart, Edward M., et al.
Publicado: (1962)

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy
por: DUINTJER TEBBENS, R. J., et al.
Publicado: (2017)

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine
por: Konz, John O., et al.
Publicado: (2021)

Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge
por: Hird, Thomas R., et al.
Publicado: (2012)

Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa
por: Cooper, Laura V, et al.
Publicado: (2022)

Metagenomic sequencing of stool samples in Bangladeshi infants: virome association with poliovirus shedding after oral poliovirus vaccination
por: Tan, Susanna K., et al.
Publicado: (2020)

Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2018)

Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization
por: Konopka-Anstadt, Jennifer L., et al.
Publicado: (2020)

Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China
por: Hu, Yuemei, et al.
Publicado: (2019)

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies
por: Resik, Sonia, et al.
Publicado: (2015)

The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines
por: Jia, Siyue, et al.
Publicado: (2020)

Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2021)

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Outbreak response strategies with type 2-containing oral poliovirus vaccines ()
por: Kalkowska, Dominika A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i4ftu61rtm66c4akhlblk0vd56